Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06006247Phase 2Completed

Early Parkinson's Disease Monotherapy With CVN424

Role: lead

NCT05635461Phase 1Completed

Relative Bioavailability and Food Effect Study of CVN424

Role: lead

NCT04191577Phase 2Completed

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

Role: lead

NCT03657030Phase 1Completed

Study of CVN424 in Healthy Subjects

Role: lead

All 4 trials loaded